SEC Form 4 · accession 0001209191-16-137007
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil F. McFarlane
Officer — Chief Operating Officer
Period of report
Aug 15, 2016
Accepted (ET)
Aug 15, 2016 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 15, 2016 | A | 15,000 | $0.00 | A | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $17.62 | Aug 15, 2016 | A | 120,000 | A | — | Aug 14, 2026 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1One-third of the shares subject to the option shall vest and become exercisable on the one-year anniversary of the date of grant, and the remaining shares shall vest in eight equal quarterly installments thereafter.